SUPPORT / SAMPLES & SAS NOTES
 

Support

Problem Note 58690: SAS® Drug Development 4.5 - Java cross-site scripting vulnerability

DetailsAboutRate It

In SAS® Drug Development, it is possible that malicious Java script could be executed. This is a form of a Java cross-site scripting vulnerability. The user interface is potentially susceptible to these exploits in the following places within the web user interface Dashboard message and notification task setup message:

  • Creating a link with no quotation marks: "javascript:prompt()"
  • Edit an existing link with, no quotation marks: "javascript:prompt()"

To obtain a fix for this issue, contact SAS Technical Support.

See this link for additional details, as these are widely known vulnerabilities:

Wikipedia: Cross-site scripting



Operating System and Release Information

Product FamilyProductSystemProduct ReleaseSAS Release
ReportedFixed*ReportedFixed*
SAS SystemSAS Drug DevelopmentLinux for x644.5.34.5.49.4 TS1M19.4 TS1M3
* For software releases that are not yet generally available, the Fixed Release is the software release in which the problem is planned to be fixed.